Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.13 USD
-0.02 (-1.74%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.15 +0.02 (1.77%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 261 - 274 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q3 Update: Cash Runway into Q4 2018 and Two New Large Market Clinical Programs for DME and wet AMD; Reiterate OUTPERFORM and $28 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Advisory Call: SCS-Microinjection Advantages vs. IVT Drug Delivery for ME-RVO and Gene Therapy for the Eye; Reiterate OUTPERFORM and $28 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
AAO: Phase 2 Details for Zuprata Treatment of ME-RVO Reinforce Top Line Results In Our View; Reiterate OUTPERFORM and $28 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Ophthalmology Expert Call: Next Generation Drug Delivery into Suprachoroidal Space Highlights Best-In-Class Profile; Reiterate OUTPERFORM and $28 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Differentiated Zuprata ME-NIU -Clinical Results Presented in High Profile Session at ASRS; Reiterate OUTPERFORM and $28 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q2 Financials Update; Sufficiently Capitalized Through Pivotal Data in 2017; Reiterate OUTPERFORM and $28 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Additional Top Line Phase 2 Results Strengthen Zuprata(TM)''s Clinical Profile for ME-RVO, In Our View; Reiterate OUTPERFORM and $28 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L